📊 CTKB Key Takeaways
Investment Thesis
Cytek Biosciences exhibits severe operational challenges with negative operating and net margins of -20% and -33% respectively, despite maintaining a healthy gross margin of 51.8%. The company is burning cash with negative free cash flow of -8.8M and negative operating cash flow, indicating unsustainable operations that will deplete the current cash position within 10+ years at current burn rates. Strong balance sheet liquidity and minimal debt provide a temporary cushion, but the core business is not generating profits and revenue growth is negligible at 0.5% YoY.
CTKB Strengths
- Exceptional gross margin of 51.8% demonstrates pricing power and efficient manufacturing
- Strong balance sheet with $90.9M cash and minimal debt ($525K), providing runway for turnaround
- Solid liquidity position with 5.04x current ratio and 4.42x quick ratio
CTKB Risks
- Severe profitability challenge: -$66.5M net loss with negative operating income of -$40.4M signals fundamental operational issues
- Negative free cash flow of -$8.8M and negative operating cash flow indicate unsustainable cash burn despite positive gross profit
- Stagnant revenue growth at only 0.5% YoY with deteriorating EPS (-550% YoY) suggests inability to scale profitably
- Negative ROE (-19.5%) and ROA (-14.4%) indicate destruction of shareholder value
Key Metrics to Watch
- Path to operating profitability and timeline for positive EBITDA
- Operating expense reduction efforts and SG&A as percentage of revenue
- Operating cash flow trajectory and cash runway at current burn rate
- Revenue growth acceleration and gross margin sustainability
CTKB Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 5.04x current ratio provides a solid financial cushion.
CTKB Profitability Ratios
CTKB vs Default Sector
How Cytek Biosciences, Inc. compares to Default sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
CTKB Balance Sheet & Liquidity
CTKB 5-Year Financial Trend
5-Year Trend Summary: Cytek Biosciences, Inc.'s revenue has grown significantly by 57% over the 5-year period, indicating strong business expansion. The most recent EPS of $0.00 indicates the company is currently unprofitable.
CTKB Growth Metrics (YoY)
CTKB Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $51.5M | N/A | $0.01 |
| Q2 2025 | $45.6M | N/A | $-0.04 |
| Q1 2025 | $41.5M | -$6.2M | $-0.05 |
| Q3 2024 | $48.0M | N/A | $0.01 |
| Q2 2024 | $46.6M | N/A | $-0.03 |
| Q1 2024 | $37.1M | N/A | $-0.05 |
| Q3 2023 | $40.5M | N/A | $-0.01 |
| Q2 2023 | $40.2M | -$702.0K | $0.00 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
CTKB Capital Allocation
CTKB SEC Filings
Access official SEC EDGAR filings for Cytek Biosciences, Inc. (CIK: 0001831915)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Mar 13, 2026 | 4 | xslF345X05/form4-03132026_100343.xml | View → |
| Mar 12, 2026 | 4 | xslF345X05/form4-03122026_080314.xml | View → |
| Mar 12, 2026 | 4 | xslF345X05/form4-03122026_080318.xml | View → |
| Mar 12, 2026 | 4 | xslF345X05/form4-03122026_080302.xml | View → |
| Mar 12, 2026 | 4 | xslF345X05/form4-03122026_080314.xml | View → |
❓ Frequently Asked Questions about CTKB
What is the AI rating for CTKB?
Cytek Biosciences, Inc. (CTKB) has an AI rating of SELL with 85% confidence, based on fundamental analysis of SEC EDGAR filings.
What are CTKB's key strengths?
Exceptional gross margin of 51.8% demonstrates pricing power and efficient manufacturing. Strong balance sheet with $90.9M cash and minimal debt ($525K), providing runway for turnaround.
What are the risks of investing in CTKB?
Severe profitability challenge: -$66.5M net loss with negative operating income of -$40.4M signals fundamental operational issues. Negative free cash flow of -$8.8M and negative operating cash flow indicate unsustainable cash burn despite positive gross profit.
What is CTKB's revenue and growth?
Cytek Biosciences, Inc. reported revenue of $201.5M.
Does CTKB pay dividends?
Cytek Biosciences, Inc. does not currently pay dividends.
Where can I find CTKB SEC filings?
Official SEC filings for Cytek Biosciences, Inc. (CIK: 0001831915) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CTKB's EPS?
Cytek Biosciences, Inc. has a diluted EPS of $-0.09.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.